Houston-based iownit.us got the green light from the Financial Industry Regulatory Authority. Getty Images

For Rashad Kurbanov, this day has been a long time coming. The founder of iownit.us has been building his digital investment platform for two years, and now the company has been approved for membership by the Financial Industry Regulatory Authority.

As a FIRA member, IOI Capital and Markets LLC, a wholly owned subsidiary of iownit.us, the company can be placement agent for digital private securities that are issued on the iownit.us platform.

The iownit.us' blockchain-backed technology allows for a more simplified and streamlined process for securities investment, making it easier on both the investors and the companies seeking investment.

"We believe our platform will reduce friction in the market and reduce costs for all market participants, while importantly providing appropriate investor protections," Kurbanov says in the release.

Kurbanov indicates in the release that the length of the approval process wasn't that surprising.

"As any new technology being introduced in financial markets, blockchain had to be thoroughly evaluated by the regulators to ensure its application in compliance with regulations that made the U.S. capital markets envy of the world," he says. "We spent a significant amount of time with FINRA and SEC Staff on productive discussions working through the use of distributed ledger technology and how it can be implemented to provide convenient yet secure platform."

Iownit.us represents a more modern approach to traditional investing processes in an increasingly digitized world.

"We are not here to 'revolutionize' investing, but we do intend to make it vastly more modern and less complicated for both issuers and investors to engage and transact," he says in the release.

In June, the company closed a $4.5 million Seed round of investment. Kurbanov said that those funds would be use to wrap up this approval process. Now that it's all squared away, the remaining funds will go toward business development and marketing initiatives and technological advancements.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”